Dr. Vince Clinical Research
  • Home
  • About
    • Leadership
    • Vision
    • Envisioned Around Technology
    • Green Certification
    • Careers
    • Photo Gallery
  • Services
    • Clinical Pharmacology Unit
    • Study Types
      • Human Abuse Potential
      • Early QT/TQT
    • cGMP Pharmacy
    • Support Services
  • News
  • Blog
  • Contact Us
  • Participate In A Study
Select Page

Dr. Vince Clinical Research Announces Dosing of Aclaris Therapeutics’ Phase 1 MAD Study of ATI-2138

by Salvador Solis | Jan 11, 2023 | Uncategorized

OVERLAND PARK, KS; January 10, 2023—(BUSINESS WIRE) Dr. Vince Clinical Research (DVCR), an early phase CRO specializing in Phase 1 trials, announced that it has administered the first dose of Aclaris Therapeutics’ ATI-2138, in a Phase 1 multiple ascending...

Dr. Vince Clinical Research Strengthens Investigator Team with the Addition of George Atiee, MD

by enewman | Dec 9, 2022 | Uncategorized

OVERLAND PARK, KS, December 12, 2022 (Globe Newswire) – Dr. Vince Clinical Research (DVCR) announced the addition of highly experienced investigator George J. Atiee, M.D. to the medical team at its world-class clinical pharmacology unit. Dr. Atiee has been...

Dr. Vince Clinical Research Announces Dosing of Ensysce’s PF614 Compound in Human Abuse Potential Trial

by enewman | Nov 8, 2022 | Uncategorized

OVERLAND PARK, Kan.; November 8, 2022 (ACCESSWIRE) – Dr. Vince Clinical Research (DVCR), a world-class early phase contract research organization (CRO) specializing in the conduct of Phase I clinical trials, today announced that it has administered the first dose in...

Cingulate Completes Fed/Fast Study Assessing Food Effect with CTx-1301, Lead Candidate for Treatment of ADHD

by Salvador Solis | Nov 2, 2022 | Uncategorized

Study Conducted by Dr. Vince Clinical Research KANSAS CITY, Kan., Nov. 01, 2022 (GLOBE NEWSWIRE) — Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and...

Dr. Vince Clinical Research Opens Industry-Leading Clinical Pharmacology Unit

by enewman | Sep 21, 2022 | Uncategorized

OVERLAND PARK, Kan.–(BUSINESS WIRE)–Dr. Vince Clinical Research (DVCR), today announced the launch of its new, world-class clinical pharmacology unit and headquarters in Overland Park, Kansas. The custom-built, green-inspired research complex was...

WCG IRB Expands Phase I Review Services, Partners with Dr. Vince Clinical Research

by enewman | Sep 17, 2022 | Uncategorized

PRINCETON, N.J. & OVERLAND PARK, Kan.–(BUSINESS WIRE)–WCG, the world’s leading provider of solutions that measurably improve the quality and efficiency of clinical research, today announced the expansion of its Phase I review services, providing...
« Older Entries

Recent Posts

  • Dr. Vince Clinical Research Announces Dosing of Aclaris Therapeutics’ Phase 1 MAD Study of ATI-2138
  • Dr. Vince Clinical Research Strengthens Investigator Team with the Addition of George Atiee, MD
  • Dr. Vince Clinical Research Announces Dosing of Ensysce’s PF614 Compound in Human Abuse Potential Trial
  • Cingulate Completes Fed/Fast Study Assessing Food Effect with CTx-1301, Lead Candidate for Treatment of ADHD
  • Dr. Vince Clinical Research Opens Industry-Leading Clinical Pharmacology Unit

Recent Comments

    Contact Us

    (913) 333-3000

    Headquarters

    7401 W. 91st Street
    Overland Park, KS
    66212 USA

    ABOUT

    • Leadership
    • Vision
    • Envisioned Around Technology
    • Green Certification
    • Photo Gallery

    SERVICES

    • Clinical Pharmacology Unit
    • Study Types
    • cGMP Pharmacy
    • Support Services

    Connect with us!

    • Follow
    • Follow
    Contact Us Today

    Privacy Policy | Terms & Conditions